Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04592549 · ClinicalTrials.gov registry record · Phase 1
Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19
A Phase 1 study, sponsored by Alachua Government Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT04592549 is a Phase 1 study that has completed, run by Alachua Government Services. The registered enrollment target is 48 participants.
The verdict
NCT04592549, a Phase 1 study, has completed, sponsored by Alachua Government Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, pharmacokinetics, and immunogenicity of ADM03820 administered as IM injections in healthy adults for the prevention of COVID-19.
Interventions
- OTHER Placebo
- DRUG ADM03820
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-12-04 |
| Est. Completion | 2023-10-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04592549
The ClinicalTrials.gov registry entry for NCT04592549 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alachua Government Services, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04592549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04592549 about?
NCT04592549 is a clinical study titled "Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19". This is a phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, pharmacokinetics, and immunogenicity of ADM03820 administered as IM injections in healthy adults for the prevention of COVID-19.
What is the current status of trial NCT04592549?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2020-12-04. Estimated completion is 2023-10-06.
What interventions are being tested in trial NCT04592549?
The interventions under investigation include: Placebo (OTHER), ADM03820 (DRUG).
Who is sponsoring clinical trial NCT04592549?
This trial is sponsored by Alachua Government Services, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.